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Abstract: Lactose is a unique component of breast milk, many infant formulas and dairy products,
and is widely used in pharmaceutical products. In spite of that, its role in human nutrition or
lactose intolerance is generally not well-understood. For that reason, a 2-day-long lactose consensus
meeting with health care professionals was organized in Mexico to come to a set of statements for
which consensus could be gathered. Topics ranging from lactase expression to potential health
benefits of lactose were introduced by experts, and that was followed by a discussion on concept
statements. Interestingly, lactose does not seem to induce a neurological reward response when
consumed. Although lactose digestion is optimal, it supplies galactose for liver glycogen synthesis.
In infants, it cannot be ignored that lactose-derived galactose is needed for the synthesis of glycosylated
macromolecules. At least beyond infancy, the low glycemic index of lactose might be metabolically
beneficial. When lactase expression decreases, lactose maldigestion may lead to lactose intolerance
symptoms. In infancy, the temporary replacing of lactose by other carbohydrates is only justified
in case of severe intolerance symptoms. In those who show an (epi)genetic decrease or absence of
lactase expression, a certain amount (for adults mostly up to 12 g per portion) of lactose can still be
consumed. In these cases, lactose shows beneficial intestinal-microbiota-shaping effects. Avoiding
lactose-containing products may imply a lower intake of other important nutrients, such as calcium
and vitamin B12 from dairy products, as well as an increased intake of less beneficial carbohydrates.
Keywords: lactose; lactose replacers; lactose intolerance; lactose maldigestion; lactase; galactose;
microbiota; infants; children; adults
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1. Introduction
Lactose, as a unique carbohydrate in most mammalian milks, has been part of the human diet
since our very origin. Nowadays, because of its chemical characteristics, lactose is found in many
milk-derived products and is an important raw material in pharmaceutical products [1,2]. There are
still questions, however, about the role of lactose (and thus dairy) in (1) infants and young children
with symptoms of lactose intolerance, and (2) children and adults who are lactase non-persistent (LNP).
LNP individuals hardly digest lactose and may show or develop symptoms of lactose intolerance [3–5].
Although dairy was introduced relatively late in the human diet, it appeared to be beneficial to
its consumers, which resulted in initial mutations, leading to the ability to hydrolyze lactose lifelong
(lactase persistence; LP). This created the opportunity to consume milk in relevant portions, thereby
providing proteins of high biological value, and vitamins and minerals such as calcium [6,7]. Moreover,
lactose in milk has a low glycemic index, which is generally considered a metabolic advantage.
Recently, other benefits of lactose consumption via milk have been identified or suggested: shaping
of the intestinal microbiota [8,9], exerting no neurologically rewarding effects when ingested [10,11],
supporting immune function [12], and facilitating mineral absorption [13].
In recent years, the use of lactose-reduced or lactose-free infant formulae is, however, increasing
in various countries, including Mexico. This is even the case for healthy infants and young children,
who fully express the lactase enzyme and can, therefore, properly digest lactose. One of the contributing
factors to this phenomenon could be the misdiagnosis of childhood functional gastrointestinal disorders
(FGIDs) where complaints are incorrectly attributed to poor digestion of lactose. This, combined with
the level of distress that the parents perceive in these situations, might explain, at least partly, why the
transition to lactose-free or lactose-reduced formulae is so easily made [14,15]. Fear for "adverse"
effects of milk/lactose consumption in early life may impact later stages of childhood and adolescence
by reduction or elimination of milk from the diet, a habit that may lead to insufficient consumption of
important nutrients needed for growth.
The purpose of the consensus meeting was to discuss and formulate a number of statements about
lactose that represent the latest scientific insights and correct existing myths. This paper describes the
discussions and provides the background on which the final statements were based.
2. Methods
To reach consensus on the nutritional and clinical importance of lactose, a total of 22 leading
Mexican experts (representing the fields of pediatrics, gastroenterology, neonatology, clinical chemistry,
genetics, endocrinology, and nutrition) from across the country, together with 2 experts from the
Netherlands, convened in a 2-day meeting in Tequisquiapan, Querétaro, Mexico. Before the meeting
and based on common questions about lactose, a set of statements was prepared. Next to that,
8 participants (topic leaders), considered to be experts in the field, were asked to prepare 30 min
presentations on one of the statements. Presentations were given during the 2-day-meeting and
each of the statements was extensively discussed within the group and amended where necessary.
Consensus was achieved by incorporating all comments from participants into a written summary of
the discussion for each topic. The summary documents were transformed into the present manuscript,
including latest relevant publications, and were thoroughly reviewed by the topic leaders. The list of
approved statements is presented in Section 3.14. Agreement on statements was given by each of the
participants by email or oral communication.
3. Results
3.1. Lactose
The disaccharide lactose, with chemical structure galactose-β1,4-glucose, has been evolutionary
conserved in virtually all placental mammalian milks, albeit in varying concentrations depending on
the species [1]. Compared to milk from other mammals, human milk is considered unique in its high
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sugar content; it contains about 70 g/L lactose (7%) contributing around 40% of the caloric value [10].
In solution, it exists in two basic configurations, α and β-lactose, which are continuously converted
into each other through a process called mutarotation. They differ in the position of the hydroxyl
group on the C1 atom of the glucose molecule, but both configurations display identical digestion
and metabolism characteristics in vivo [16]. The specific β-1,4 glycosidic bond between galactose and
glucose is relatively rare in nature (although also present in cellulose and chitin). It may protect the
lactating breast or neonatal gastrointestinal tract (GI tract) against infection by selective limitation
of environmental microorganisms that have more difficulties with fermenting lactose compared to
simple, alpha-linked glucose polymers. As such, lactose may be important in the early shaping of
the neonatal gut microbiota [1]. The importance of lactose in the process of lactation is evidenced by
various evolutionary adaptations by mother and child. In the mammary gland, lactose is completely
synthesized from glucose provided by the arterial blood supply, and has low solubility (only 10% that
of sucrose at 25 ◦C) but high stability in solution, thereby preventing lactose from diffusing out of the
Golgi and secretory vesicles [17]. As a consequence, lactose can be easily secreted and aid in drawing
water into these organelles, as such, determining the volume of the milk produced. The stability of
lactose in solution enables the body to transfer significant amounts of energy to the neonate without
excessive osmotic effects [17].
Several physiological benefits have been attributed to lactose in breast milk. Besides serving
as an energy source, lacking any rewarding effects, unlike other carbohydrates such as sucrose or
maltodextrin [10,11], it provides glucose and galactose, which serve as building blocks for various
macromolecules (e.g., oligosaccharides, glycoproteins, and glycolipids) [18]. In addition, lactose is the
least cariogenic amongst fermentable sugars [19], possesses a low glycemic index (GI = 46) [20] and
can exert microbiota-modulating effects in the case of sufficient passage of undigested lactose into
the lower intestine [8,9]. Furthermore, enzymatic hydrolysis into its monosaccharides is considered a
re-hydration mechanism in the small intestine [21]. Lactose is widely used in food and pharmaceutical
industries. Applications range from an energy source for lactic acid bacteria during dairy-product
fermentation, in which its breakdown leads to the formation of specific flavor components, to its use as
an excipient in oral, solid-dose pharmaceutical formulations [2].
3.2. Lactase (LCT)
Lactose needs to be broken down into its monosaccharides in order to be efficiently absorbed in
the small intestine. Hydrolysis is controlled by lactase (LCT, also known as β-galactosidase or lactase
phlorizin hydrolase (LPH)), a homodimeric enzyme anchored to the membranes of the small intestinal
villus tips, with its highest expression being in the brush border of the mid-jejunum [22]. Maturation
of the machinery for carbohydrate digestion and absorption occurs in a defined sequence during
fetal development. Providing an adequate amount of nutrients is very important in order to reduce
morbidity; however, the immature gastrointestinal system may represent a limitation. Therefore,
understanding gastrointestinal development, which directly affects the metabolism of lactose, is key as
it relates to the accretion of nutrients beneficial to the infant. Intestinal lactase activity is detectable
in the fetal gut by eight weeks of gestation. Whereas sucrase, maltase, and isomaltase are usually
almost fully active in preterm infants, lactase activity is low and proportional to gestational age (in
infants <34 weeks, enzyme activity amounts to approximately 30% of that at term), but increases
markedly from 24 to 40 weeks [23]. After the first feeding, there is a rapid increase in lactase activity to
promote digestion of the lactose present in breast milk [24,25]; lactase-mediated hydrolysis of lactose
typically exceeds 98% efficiency within five days of starting feeding [26]. Age, feeding, and nutrient
composition have been shown to affect the development of intestinal lactase activity [27–29]. Premature
babies that received early enteral feeding exhibited greater enzyme activity (100%) than infants in
the control group (60%) [30]. Moreover, at 10 days old, lactase activity was higher in newborns that
were fed with breast milk rather than formula [30]. Despite this relative “lactase deficiency” in the
preterm infant, clinical symptoms of lactose intolerance are uncommon and the use of lactose is,
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therefore, not contraindicated [31]. Postnatal adaptive responses to carbohydrates ingested by the
colonic microbiota further improve lactose digestion; even an excess of lactose that goes undigested by
lactase in the brush border will be effectively fermented in the terminal ileum and colon by conversion
into short-chain fatty acids [30]. During childhood and in a majority of children, lactase levels gradually
decrease from a peak at birth to less than 10% of the preweaning level, with most of the change being
observed at an age of about 2 years or older. However, lactase activity may persist into adulthood
in some (sub)populations, which will be addressed in the next paragraph. Finally, congenital lactase
deficiency has been described, but is rare; therefore, nutritional restriction of lactose is generally not
necessary in term infants and children [4,28].
3.3. Development of Lactase Persistence (LP)
Physiological down-regulation of lactase expression by 90%–95% occurs in the majority of humans
(~65%) post-weaning in the absence of intestinal injury or disease, a wild-type condition known
as lactase non-persistence (LNP) [3,32]. Lactase activity persists, however, in some populations, a
condition known as lactase persistence (LP), which can be attributed to (differential) regulation of
lactase biosynthesis. Historically, the practice of pastoralism with its associated increase in consumption
of milk and milk-derived products triggered this development of LP. These are all relatively recent
events which significantly impacted our culture, biology, genetics, and behavior. LP is the most
strongly selected single-gene trait currently known that evolved in Europeans and some African and
Asian groups over the last 10,000 years [33–37]. The estimated spread of LP in Europe is thought to
have been a very fast process. In fact, it has been calculated that the percentage of the population
surviving to reproductive age increased by 5%–10% each generation due to the development of this trait,
indicating that LP must have provided strong health benefits [6,7]. To date, it is unclear when LP exactly
developed; data suggests anywhere between 4000 and 7500 years ago, probably in Central Europe [6].
Early evidence of animal domestication in southwestern Asia extends back to around 12,000 years
ago. While initially, domestic animals were exclusively exploited for their primary products in the
early Neolithic era, the widespread use of their secondary products—particularly milk—followed
immediately or very soon after [38–40]. Dairying seems to predate the development of LP by several
millennia, which might be explained by the initial consumption of fermented milk products, as these
contain reduced lactose levels, causing no intolerance symptoms. Thus, in the developing pastoral
societies of Eurasia, LP may have evolved as an adaptation to the consumption of fresh dairy products,
thereby improving daily nutrition. Considering the varied ecologies in which LP evolved, it is unlikely
that one single hypothesis explains the strong signatures of natural selection inferred across multiple
geographical regions.
3.4. Regulation of Lactase Expression
Lactase is composed of two monomers, each consisting of two catalytic sites: domain III
(phlorizin-hydrolase; beta-glucosidase activity) and domain IV (lactase; beta-galactosidase activity) [41].
LCT is located on the long arm of chromosome 2, is composed of 17 exons [3], and is primarily regulated
at the transcriptional level [32]. The current view is that after lactase activity has been fully established,
it is not influenced by dietary changes and/or lactose intake any longer [32]. Rather, differential lactase
expression (as previously indicated, highest in the mid-jejunum) is orchestrated by gut-region-specific
expression of the many transcription factors [22]. On a molecular level, epigenetic silencing in the
condition of LNP takes place in both an upstream enhancer, located in intron 13 of the “DNA replication
licensing factor MCM6” gene [42], and the promoter region of LCT itself [43,44]. LP is caused by well
described single nucleotide polymorphisms (SNPs) in the enhancer, and these genetic changes prevent
the epigenetic silencing of lactase after weaning [42]. Interestingly, in some populations, substrates for
the phlorizin hydrolase domain of LCT might have driven development and evolutionary selection
of LP. In these LP populations, a variety of triggers for lactase biosynthesis might have provided
individuals the capability to detoxify certain nutrients (e.g., phlorizin) or increase the bioavailability of
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beneficial substrates like flavonoids (e.g., quercetin) [45]. Although the prevailing view is that there
are no lactase-inducing or silencing signals from the environment, accumulating evidence (epigenetics
and in vitro studies [46–48]) suggest that this cannot be excluded.
3.5. Lactose Maldigestion and Intolerance, and Lactose Replacements
The non-immune mediated intolerance to carbohydrates is primarily due to maldigestion because
of deficiency of enzymes or transporters, or is caused by overloading of intestinal brush border
digestive/transport systems. Non-digested/-absorbed carbohydrates are readily fermented by the
intestinal microbiota, resulting in the production of fermentation products, such as lactate, short-chain
fatty acids (SCFAs), and several gasses (CO2, H2, and CH4). Severe maldigestion of carbohydrates
may cause osmotic diarrhea [5,49,50].
Symptomatic lactose intolerance is the result of an impaired lactase capacity to properly digest
lactose [3]. Congenital lactase deficiency, is an extremely rare, autosomal recessive condition caused
by mutations in the lactase gene resulting in complete lactase absence [51,52]. Early in life, it is
hypothesized (but unproven) that lactose maldigestion may, in rare cases, be caused by temporary
lactase insufficiency (developmental or neonatal lactase deficiency) which generally resolves at three
months of age, coinciding with the period of colicky behavior, although the role of lactose in infantile
colic is controversial. Secondary lactase deficiency is a temporary decrease in lactase activity due to,
for instance, damage of the intestinal villi of the small intestine. This may occur at any age, both in
LNP and LP individuals. In the majority of people, and most often from late childhood onwards,
lactose malabsorption has a genetic background (primary, adult-onset lactase deficiency) [4,5]. Lactose
maldigestion and/or lactose malabsorption may result in clinical symptoms, such as distension of the
small bowel, non-focal abdominal pain associated with bloating and flatulence, nausea, increased gut
motility, and diarrhea. Additional systemic symptoms, such a headache, vertigo, memory impairment,
and lethargy, have been described in less than 20% of subjects. It has been hypothesized that these
symptoms could be caused by toxic metabolites derived from sugar and amino acid fermentation [50].
It is noteworthy that, out of these two types of fermentation, carbohydrate fermentation is linked
predominantly to metabolic benefits of the host, whereas the more distal colonic fermentation of
peptides and proteins is more closely associated with the production of harmful metabolites [53].
Although lactose maldigestion has been proposed as a factor involved in functional gastrointestinal
disorders (FGIDs) [54–59], no conclusive evidence for a direct relation has been shown [4,26,60,61].
In order to address lactose intolerance (maldigestion) and associated (clinical and nutritional) issues,
lactose replacement and restriction strategies have widely received attention. According to the
CODEX Alimentarius [62], glucose polymers can replace lactose in infant formulae to meet the caloric
requirements. Based on effects of glucose and sucrose overconsumption in children, it has been
hypothesized that regular consumption of lactose substitutes in infant formulae may represent a
potential risk factor for the development of overweight or obesity. The following paragraphs will
address the various aspects involved in the diagnosis, functional consequences, and treatment of lactose
intolerance. In addition, the short and long-term effects of lactose replacements on key physiological
parameters will be highlighted.
3.6. Diagnosis of Lactose Intolerance
The incidence of lactose intolerance depends on the diagnostic method used and the amount
of lactose used in the test. While a lactase activity assay in jejunal biopsies is the gold standard
for diagnosis, the lactose hydrogen (H2) and/or methane (CH4) breath test is more practical and
less invasive [63–65]. To discriminate between hydrogen and methane producers, and fast or slow
fermenters, a pre-screening test with lactulose (always fermented) can be performed [66]. Finally,
lactose exclusion or reduction (during 2–4 weeks) to achieve symptomatic improvement, followed
by gradual lactose reintroduction, has proven useful and is often applied [66]. With regard to the
dose of lactose used for intolerance tests, the commonly-used dose of 50 g may not be realistic, since
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this is the equivalent of 1 liter of milk, which is highly unlikely to be consumed at once in practice.
Therefore, 25 g might represent a more suitable provocation dose, at least for adults [67]. An even
better alternative might be the implementation of a dairy product tolerance test (e.g., drinking 250 mL
of milk) with symptom evaluation up to 24 hours post-consumption and the inclusion of an H2/CH4
breath test [68,69]. For infants and children, a H2/CH4 breath test and elimination-provocation diets,
using physiological doses (2 g/kg of body weight) of lactose, are commonly used [4,60].
3.7. Possible Consequences of Lactose Restriction
Once lactose intolerance has been diagnosed, it is important to identify its severity and underlying
cause. Most infants digest lactose very well and a lactose-restricted diet is only necessary for a
limited period of time in case of transient lactase deficiency (due to, for instance, intestinal epithelial
damage). In subjects with LNP (typically older children and adults), varied amounts of lactose are
still tolerated without the presentation of significant symptoms. Generally, individuals with LNP can
consume up to 12 g of lactose in a single dose with no or only minor intolerance symptoms [5,70].
In addition, the oral administration of β-galactosidase (exogenous lactase) can improve tolerance to
lactose-containing foods [5]. In the absence of formal guidelines, the American Academy of Pediatrics
and the National Institutes of Health published general recommendations for the management of
lactose intolerance [60,71].
Currently, no data exist on the long-term effects of lactose restriction in children. However, since
lactose is a unique and major carbohydrate in mammalian milk, the exclusion of lactose containing
milk and dairy-derived products also implies a restriction of the other nutrients present in these
products. Dairy products are important sources of bioavailable calcium, vitamin D (when added),
and vitamin B12, and, over time, lactose-restriction may induce insufficiency, potentially resulting in
decreased bone mineral density, anemia, and neuropathy [5,72]. Overall, depending on the severity of
intolerance symptoms, a temporary reduction in lactose can be beneficial; however, this is no reason to
stop breastfeeding. As previously indicated, lactose maldigestion due to LNP develops in a major part
(65%–70%) of the global population from (late) childhood onwards and can, but certainly does not
always, lead to symptoms of lactose intolerance.
3.8. Lactose Maldigestion and Functional Gastrointestinal Disorders (FGIDs)
Lactose maldigestion develops when the amount of ingested lactose exceeds the capacity of
lactase activity. As indicated above, most infants and toddlers can properly digest lactose and the
likelihood of lactose maldigestion without the presence of intestinal damage factors, such as infection
or allergy, is very low. In addition, there is no robust evidence to suggest that infants and toddlers
with FGIDs present lactose maldigestion [4,26,60,61]. Under specific circumstances, however, gasses
produced during lactose fermentation can cause or worsen abdominal pain and distension [4,60].
In patients with irritable bowel syndrome and visceral hypersensitivity, a reduction of lactose and/or
other carbohydrates of the FODMAP (fermentable oligosaccharides disaccharides monosaccharides
and polyols) group has shown a significant reduction in abdominal pain and bloating [54–56]. It should
be noted that the current explanation for the occurrence of FGIDs in children and adolescents is not
that of a single-cause entity; FGIDs are recognized and identified by morphological and physiological
abnormalities that often occur in combination with other morbidities, including motility disturbances,
visceral hypersensitivity, altered immune function, altered microbiota composition and activity, and
altered central nervous system processing [57]. Additionally, stool reducing substances, i.e., unabsorbed
reducing sugars in the stool, are not associated with the occurrence of colic. In fact, they are frequently
present in the stools of healthy infants, either fed with human milk or lactose-containing formula,
under 10 weeks of age. The presence of reducing substances in the stool of infants fed with human milk
is even four times higher than that of formula-fed infants, probably due to the presence of a substantial
amount of human milk oligosaccharides [26,61,73]. In formulae, prebiotics may explain part of the
reducing sugars, but the presence of some lactose cannot be excluded. Nevertheless, reducing sugars
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do not appear to be harmful or associated with FGIDs. Taken together, lactose should not be considered
a hazardous nutrient [74].
3.9. Lactose Replacements: Metabolic Consequences of Glucose Polymers
In lactose-free or lactose-reduced infant formula, lactose is substituted by glucose polymers.
The most common glucose polymers are digestible maltodextrins, glucose syrups, and dried glucose
syrups; these glucose polymers are produced by the hydrolysis of different types of starches (corn,
rice, or potato starch) [75,76]. Starch, maltodextrins, glucose, and lactose all have a similar energy
value (4 kcal/g), but differ in the rates of digestion and absorption. Glucose is immediately available
for absorption, whereas starches, maltodextrins, and lactose need to first be digested by α-amylase,
maltase, and lactase, respectively [76]. Of note, the enzymatic digestion of maltodextrins occurs at a
high rate, resulting in post-ingestion insulin responses comparable to pure glucose.
Glucose polymers have a higher glycemic index (GI = 110) than lactose (GI = 46), and as a result,
induce a higher glycemic response. The low GI of lactose is primarily caused by the non-insulinogenic
response to galactose. This could be a metabolic advantage compared to glucose polymers that cause
a larger increase in plasma glucose and plasma insulin. For adults, this appears to be true; GI is a
valid parameter to classify diets with regard to their preventative (low GI) or provoking (high GI)
effect on diabetes, coronary heart disease, and likely obesity as well [77]. For children and adolescents,
such (preventive) low GI benefits are still under discussion. A study in infants on the effects of
consumption of lactose or corn syrup-containing formula did not reveal any differences in insulin or
blood glucose levels (based on area under the curve) over a two-hour postprandial period. However,
after two hours, the lactose group exhibited significantly higher glucose and insulin levels compared
to breastfed and corn syrup-containing formula groups [78]. It is possible that the increased glucose
levels (120 min postprandial) that were observed were partially due to both glycogenolysis (breakdown
of (galactose-derived) glycogen) and gluconeogenesis [79,80]. Another study, using urinary C-peptide
to creatine ratio as a stable marker of insulin secretion, showed a higher C-peptide secretion after the
consumption of a corn-sugar based formula compared to a lactose based formula, indicating higher
insulin levels in the former [81].
High blood glucose levels are involved in protein glycation, the non-enzymatic reaction
between glucose (or other reducing sugars) and an amine group from free amino acids or
proteins. Although initially, glycation of molecules is reversible, irriversible complexes, called
advanced glycation endproducts (AGEs), are formed over time. AGEs accumulate with age and are
linked to certain complications associated with diabetes, kidney disease, metabolic disorders, and
degenerative diseases [82,83]. Regular consumption of considerable amounts of high GI carbohydrates,
that substantially increase blood glucose levels, enhances the risk of AGE formation [84].
Limited evidence [85] suggests that maltodextrin, consisting of α-1,4 and α-1,6-linked D-glucose
chains, may disrupt host-microbial dynamics in the gut when it escapes digestion, and may be
associated with the promotion of Escherichia coli colonization. Furthermore, it was shown that in vitro
cellular exposure to maltodextrin leads to impaired anti-bacterial responses, as demonstrated by
the increased viability of intracellular Salmonella in macrophages and epithelial cells cultured in
maltodextrin-supplemented media. Although the effect of maltodextrin on Salmonella clearance in
macrophages was dose-dependent, any exposure was sufficient to increase bacterial viability [85].
In another animal study, it was recently shown that maltodextrin promotes endoplasmic reticulum
stress in intestinal Goblet cells, which leads to mucus depletion and exacerbation of intestinal
inflammation [86]. Therefore, when providing a lactose-free formula that contains maltodextrins,
changes in microbiota should be carefully monitored to get more insight in this topic. It is of interest to
note that the gut microbiota is increasingly recognized as an import part of our bodies and that changes,
and the intestinal microbiota are linked to various physiological processes, including body weight
management [87]. An increased Firmicutes/Bacteriodetes ratio and a reduced capacity to degrade
carbohydrates to short-chain fatty acids is related to metabolic dysfunction of the host organism [88].
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This also highlights the importance of maximizing efforts (via, e.g., low heat treatment) to limit
glycation of proteins during the production process of products containing proteins and reducing
sugars (such as lactose). These food-derived glycated proteins may contribute to overall obesity risk,
as the majority are not digested but fermented [83].
With regard to minerals, lactose is known to enhance the absorption and retention of calcium,
magnesium, and manganese; this is related to a pH drop due to its fermentation in the large intestine,
which increases solubility of calcium (and other minerals), thereby increasing passive absorption.
However, the functional relevance of this increased absorption is questionable, considering the surplus
of calcium that is typically added to formulae designed for infants and young children [13].
Ultimately, the risk of detrimental long-term effects on health due to providing high GI
carbohydrates early in life should be carefully considered; replacement of lactose with glucose
polymers might lead to a worse nutritional status, a change in intestinal microbiota, and reduced
calcium absorption. The effects of lactose-containing or lactose-free formula on insulin and glucose
levels in infants is less clear and largely inconclusive. Evidence for short-term effects on parameters
linked to chronic diseases is very limited. However, since nutritional preferences are shaped during
childhood, the long-term relevance of early exposure to sweet, high GI food products may be
considerable [77,82].
3.10. Lactose Replacements: Taste Preference and Obesity Risk Later in Life
Behavioral studies have indicated that in the last trimester of pregnancy, the taste buds are
able to detect and send information to the central nervous system regarding the composition of
the amniotic fluid, which illustrates that the development of the taste sense occurs at a very early
stage in life. Similarly, it has been shown that at birth, children have a preference for sweet flavors,
including carbohydrates in breast milk, which allows them to identify the sources of energy necessary
for growth [89]. This preference for sweet flavors persists during childhood and adolescence and
can potentially be a disadvantage in view of the obesogenic environment in which we live. Indeed,
the availability and consumption of a large number of industrialized products, including sugary drinks,
has been associated with the development of overweight and obesity in children and adolescents [90].
Interestingly, the sweetening effect of lactose is weak and devoid of any neurochemical stimulation (e.g.,
lactose does not evoke rewarding effects) [91]. The lack of a neurochemical response may explain why
feelings of pain in infant rats are suppressed by glucose, sucrose, and fructose, but not by lactose [92].
The pain-reducing properties of sucrose have been replicated in human newborns [93].
The use of infant formulae as substitutes for breast milk is increasingly common, particularly in
countries like Mexico, where parts of the population have abandoned the practice of breastfeeding and
the recommendations of the WHO [94]. Infant formulae are often subject to several modifications, such
as the hydrolysis of proteins, or the partial or total replacement of lactose with other carbohydrates,
such as maltodextrins, glucose syrups, and even sucrose [95]. Like many other countries in the
world, Mexico suffers from an epidemic of overweight and obesity amongst children and adolescents
(prevalence of around 35%). Although the taste for sweet flavors is innate (at least to some extent), it has
also been pointed out that regular consumption of sweetened foods and drinks can have adverse short
and long-term consequences on food preference and lead to the consumption of excessive amounts of
sugar [96]. Unfortunately, a lot of uncertainty exists regarding the regular consumption of formulae
with lactose substitutes due to a shortage of literature on this topic. Thus, at this time, it cannot be
affirmed that regular consumption of infant formulae containing lactose replacers is a risk factor for
the development of overweight or obesity. Studies comparing regular consumption of these formulae
to consumption of other foods are warranted. Eventually, assessing if the accumulation of adipose
tissue differs between children who consume infant formulae with and without lactose would be of
great value. It should be noted that, besides the potential differential effects of lactose and lactose
substitutes on food preference, lactose possesses other properties that can contribute to healthy body
weight development. Lactose has a low GI, a property that has been shown to play a subtle role in
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the prevention or treatment of childhood obesity [77]. Furthermore, if undigested lactose reaches the
lower intestine, the fermentation of lactose generates short-chain fatty acids that have been shown to
regulate body weight through effects on food intake and energy metabolism [97]. Recently, partial
replacement of glucose with galactose, resulting in a 1:1 ratio mimicking lactose, in a 3-week post
weaning diet, was shown to lower body weight, adiposity, homeostatic model assessment of insulin
resistance (HOMA-IR), and expression of insulin signaling in high fat diet-challenged female mice in
later life. These findings suggest that prolonged galactose intake may improve metabolic and overall
health for extended periods of time through galactose-mediated nutritional programming [98].
3.11. Potential Health Benefits of Lactose as a Supplier of Galactose and via Microbiota Shaping Effects
The gastrointestinal tract is colonized by different microorganisms, which participate in the mucosal
immune system through diverse mechanisms [99]. Although the GI tract microbiota’s composition,
origin and abundances are controversial, evidence suggests that important microbiota-shaping factors
include the maternal microbiota (oral, intestinal, and vaginal), circumstances and inoculation at
birth (hospital, home, and normal versus caesarean delivery), anti-biotic treatment, and food (milk)
composition. In addition, the period preceding delivery may be important, since bacteria seem to
be present in the placenta, amniotic fluid, and meconium [100–102]. Gut microbiota and the host
have a symbiotic relationship, with the former strengthening the immune system and protecting
the host against pathogens [102]. Qualitative and quantitative changes in the intestinal microbiota,
its metabolic activity, and its local distribution, affect pathobionts and pathogens in the gut, a state
known as “dysbiosis.” These changes could contribute to the development of diseases, such as
colorectal cancer, gastrointestinal disorders, obesity, allergy, and others [102–106]. Recently, the genus
Bifidobacterium has gained growing interest as it has been associated with the presence of undigested
lactose and several health benefits [104]. Other factors, such as stress, diet, and genetic background,
may also impact Bifidobacterium prevalence in the gut [107]. In the next paragraphs, we will discuss our
current knowledge on the (potential beneficial) effects of (undigested) lactose on Bifidobacteria and the
microbiota in total. In addition, the specific relevance of galactose downstream of lactose in glycogen
synthesis and possibly as an important building block for glycosylation will be addressed as well.
3.12. Lactose, Bifidobacteria, and the Microbiota: Potential Health Benefits?
Breast milk is essential in infancy because it supplies important biomolecules, including
oligosaccharides, antioxidants, IgA, and anti-inflammatory compounds, that offer protection against
diseases [105]. As indicated previously, lactose is normally cleaved into the monosaccharides glucose
and galactose by lactase in the GI tract [67]. However, if undigested, lactose reaches the terminal ileum
and colon (as explained earlier), and it is fermented by the intestinal microbiota, favoring colonization
by Bifidobacteria and other lactic acid bacteria. Additionally, in vitro studies have revealed that lactose
increases the levels of gastrointestinal antimicrobial peptides. The colonization of Bifidobacteria and
the induction of antimicrobial peptides both potentially protect, albeit independently, the neonatal
gut against infection [31]. In LNP subjects (lactase <10 u/g) and in infants that are physiological
malabsorbers of lactose, lactose can exert microbiota-modulating effects as well [8,9,108].
Lactose is fermented by members of the microbiota that can easily split the β-1,4-glycosidic
linkage. Studies in weaning pigs show a positive, dose-related effect of dietary supplementation
with lactose on intestinal Bifidobacteria and Lactobacilli, and an increase in total volatile fatty acids in
feces with a particular increase in butyric acid [109]. In infants, the addition of lactose (38 g/L) to an
extensively hydrolyzed formula resulted in significantly augmented counts of Bifidobacteria and lactic
acid bacteria, and decreased numbers of Bacteroides and Clostridia compared to a lactose-free variant.
The same study also demonstrated a positive effect of added lactose on the fecal metabolome with
increased concentrations of short-chain fatty acids (mainly acetic and butyric acid) [110]. In young
adults with lactose malabsorption (as indicated by increased exhaled hydrogen levels), whole milk
supplementation (250 mL/day, during 4 weeks) resulted in a higher relative abundance of fecal
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Actinobacteria, Bifidobacteria, Anaerostipes (butyrate producers), and Blautia (acetogenic) compared to
normal lactose digesters [111]. Next to lactose, human milk oligosaccharides (HMO) are well-known
stimulators of the neonatal intestinal microbiota [112]. Additionally, prebiotics in infant formulae
show microbiota-shaping effects (i.e., an increase in Bifidobacteria up to levels seen in breastfed infants,
accompanied by a smaller rise in Lactobacilli) [113,114]. Interestingly, galacto-oligosaccharide (GOS)
supplementation appears to be beneficial for lactose-intolerant individuals [115,116]. Stimulation of
both Bifidobacterium and Faecalibacterium activities ameliorated lactose-intolerance symptoms [117].
In fact, both a Bifidobacterium-rich fecal microbiota, associated with reduced lactose digestion, together
with increased levels of short-chain fatty acids, exerted a protective effect on colonic mucosal integrity
and early immune system development [118]. Less well-known fibers, such as fructans from Mexican
Agave plants, may exhibit these microbiota-shaping effects as well and could support the proper
fermentation of lactose [119].
As discussed earlier, lactose may also have immunomodulatory effects. Postpartum, infants do
not have fully functional adaptive immune systems and rely on the innate immune system with its
antimicrobial peptides and proteins expressed on epithelial surfaces. In vitro research suggests that
lactose may be part of this early defense system. Lactose (supplied as the hydrophilic fraction of breast
milk or as commercially-available purified lactose) induced, in vitro, the cathelicidin antimicrobial peptide
(CAMP) gene encoding the human antimicrobial peptide cathelicidin LL-37 in colonic epithelial cells
in a dose and time-dependent manner. Lactose also induced CAMP in the colonic epithelial cell line
T84, THP-1 monocytes, and macrophages. Furthermore, a synergistic effect on CAMP induction was
demonstrated with butyrate and phenylbutyrate. Although infant formulae also showed a stimulation
of CAMP, a dose-dependent effect was lacking [31]. These antimicrobial peptides, such as CAMP,
might play a role in further shaping the neonatal microbiota [12].
Many of the proposed beneficial effects of lactose can be linked to short-chain fatty acids that (1)
serve locally as energy for the gut microbiota and the cells of the intestinal wall, (2) confer a protective
effect on colonic mucosal integrity, (3) exert a beneficial effect on early immune development, and (4) are
used as energy source following absorption and transport to the liver [31,120]. Overall, it appears that
lactose can beneficially influence the gut microbiota and play a role in the development of Bifidobacteria
in the guts of LNP individuals, infants, and children. Interestingly, Bifidobacteria metabolize lactose
to short chain fatty acids and lactate, but not H2, whereas H2 can comprise up to 50% of the flatus
volume [121]. Therefore, its consumption/supplementation, albeit in adequately sub-threshold doses
with respect to lactose intolerance complaints, can lead to improved lactose tolerance.
3.13. Potential Health Benefits of Galactose
It seems unclear why nature designated lactose as the disaccharide to uniquely occur in mammalian
milk; its synthesis requires substantial investment of energy by the mother, and the breastfed infant
subsequently requires energy for its digestion. Part of the explanation could be that coupling of the
two monosaccharides glucose and galactose, reduces the osmotic pressure of milk, which by definition
is equal to the osmotic pressure of maternal plasma. Coupling allows for a higher mother-to-child
transfer of a carbohydrates that serves as a slow-release energy source and a provider of building
blocks for complex macromolecules in the infant. Following lactase-mediated hydrolysis of lactose in
the infant’s GI tract, both glucose and galactose are predominantly taken up by the sodium-glucose
linked transporter-1 (SGLT1) [122,123]. This symporter also transports sodium and water, and
co-transports calcium by bulk flow [124]. Unabsorbed lactose, as well as unabsorbed glucose and
galactose moieties and HMOs may serve as substrates for the microbiota in the infant’s colon [125].
Most of the absorbed glucose passes the liver to elicit an insulin response, which causes the majority of
galactose to become trapped in the liver [126], where it becomes a major substrate for the synthesis
of glycogen [18,123,126]. The glucose-mediated insulin-response enhances glycogen synthesis by
inhibiting a kinase or kinases, such as glycogen synthase kinase-3 (GSK-3) [127], that inactivate glycogen
synthase [123,126,128]. Although galactose is not considered an essential nutrient in general, it could
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be conditionally essential in infants in the context of rapid growth. Galactose is used for the synthesis of
a variety of oligosaccharides, glycoproteins, and glycolipids [129]. Moreover, lactose-derived galactose
could be important in assuring metabolic flexibility in infants/young children, because it behaves in
a non-insulinogenic manner (under fed conditions), and thereby lifts the break (e.g. insulin) on fat
metabolism [78]. This enables the infant to switch to fat metabolism (e.g., ketone body production)
when there is a high demand for energy, for instance during rapid growth. Amongst others, ketone
bodies are a great energy substrate for the brain, which is incapable of oxidizing fats itself.
Thus, lactose limits milk osmotic pressure, promotes uptake of sodium, water and calcium,
and acts as a microbiota-modulating nutrient, partially as unabsorbed lactose, and partially as a
source of building blocks for the more complex HMOs. Absorbed glucose and galactose serve as the
foundation for macromolecules, a rapidly available energy source (glucose), and ‘storage’ in the form
of mobilizable glycogen in the liver (generated from galactose) [18].
3.14. Consensus Statements
The participants of the consensus meeting adopted the following statements:
Lactose does not differ in biochemical-structural composition between mammalian milks, and it
is a unique carbohydrate in nature with beneficial properties in most people.
Lactase activity is detectable in the fetal gut by eight weeks of gestation; and at least from
32 weeks of gestational age onwards until late childhood or longer, lactose (6–7 g/100 mL) can be
digested sufficiently.
Lactase expression in case of primary, adult-onset lactase deficiency, does not stop at a precise
moment in time: its down-regulation is the result of an incompletely understood, internal, epigenetic
developmental program.
Lactase persistency is a very strongly and positively selected genetic trait that significantly
increased survival rates after it arose, amongst others, by improving daily nutrition. Nowadays,
approximately 35% of the world’s population is lactase persistent.
Lactose maldigestion (any undigested lactose) is not a clinically relevant issue in infants and
children, unless symptoms of lactose intolerance or symptoms related to GI diseases, such as celiac or
Crohn’s disease, are severe.
Lactose maldigestion is not a harmful process when the dose does not exceed the fermentation
capacity of the intestine and is not related to functional gastrointestinal disorders.
Lactase non-persistent children and adults still can consume lactose without symptoms of
intolerance but the tolerable amounts are variable and depend on several factors. It is said that up
to 12 grams of lactose in a single dose is well tolerated, and when combined with a meal and/or
distributed over the day, even higher amounts are well tolerated by many maldigesters.
Lactose contributes to the development of a Bifidobacteria-rich microbiota and may act as a
microbiota-shaping carbohydrate especially in LNP persons but also in LP infants and children.
Dietary galactose, in combination with glucose (simultaneously delivered to the body, in the
case of lactose), plays an important role in infant’s and children’s nutrition in the replenishment of
liver glycogen.
Exogeneous galactose supply (e.g., via lactose) may be needed under conditions of growth
and development (e.g., infants and young children) as a structural building block for glycosylated
macromolecules (e.g., galactocerebrosides for myelination by oligodendrocytes in the brain).
The consumption of high GI maltodextrins and the consecutive rise in blood glucose levels may not
be favorable for infants and children in the long run because of its impact on inflammatory pathways.
Lactose is preferred over lactose replacers in infant’s and children’s nutrition because of its weak
sweet taste and the fact that lactose consumption does not elicit any rewarding effects. Lactose could,
therefore, lead to less imprinting of sweet taste at a young age, and therefore, reduce the preference for
sweet flavors later in life.
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The potentially beneficial impact of lactose on overweight development in children is at the
moment, not scientifically validated. Specifically-designed longitudinal scientific studies are needed to
clarify this potential link.
4. Discussion
Lactose, synthesized in the mammary gland, is nature’s way to get a significant quantity of
carbohydrates in milk, and largely determines the volume of milk produced and provides a relevant
portion of slow-release energy [17]. Since lactose is the primary carbohydrate in most mammalian
milks and its concentration in milk cannot be influenced by the maternal diet, it is obvious that
lactose is the preferred carbohydrate in infant and young child formulae. However, the use of
lactose-reduced or lactose-free formulae in several countries is increasing. The main driver for this
is the often-false coupling of symptoms of intestinal discomfort to (perceived) lactose intolerance.
From childhood onwards, lactose maldigestion is established in the majority of the world’s population
because of a genetically-driven down-regulation of lactase expression (LNP) [3,32]. The proposed
benefits of lactose (energy source without rewarding effects, supplier of galactose and glucose, low
GI, microbiota-modulating activity, and low carcinogenicity) [8–11,20,21] necessitate a careful, well
thought-out approach for managing lactose maldigestion. During this workshop, the attendees
discussed the available evidence for the proposed benefits of lactose, the clinical aspects of lactose
intolerance, and the importance of lactose for infants, children, and adults, both in the context of LNP
and LP. This resulted in the drafting of the 13 statements presented in this document (see Section 3.14.
Consensus Statements).
When lactose is digested, the absorbed glucose passes the liver to elicit an insulin response, which
causes the majority of galactose to become trapped in the liver [126], acting as a major substrate for
the synthesis of liver glycogen [18,123,126]. Any toxic effects of galactose, as supplied by lactose,
are neglectable. Even after the ingestion of 100 g of lactose, the maximum concentration of galactose in
the systemic circulation stays ≤1 mmoL/L [79]. Taking into account that the maximal recommended
daily dose of galactose is 50 g for a healthy adult, liver galactose clearance capacity appears to be high
enough under normal circumstances [130]. However, the ingestion of galactose without glucose or
with alcohol consumption induces higher, non-pathological plasma concentrations of galactose [79].
In the liver, galactose is converted by the enzyme galactokinase into galactose-1-phosphate, which
is converted into uridine diphosphate (UDP)-galactose, UDP-glucose, and next into glycogen, or it
is transformed into glucose-1-phosphate [79,80,131]. Pathologically elevated blood galactose levels
may occur because of deficient functioning of enzymes involved in galactose metabolism (e.g., GALK
(galactokinase), GALT (galactose-1-phosphate uridyl transferase), or UDP-Galactose-4 epimerase
(GALE)), a rare condition known as galactosemia [132]. Individuals suffering from this disease
accumulate certain galactose metabolites (galactitol and galactose-1-phosphate) leading to damage of
the eye lens, liver, kidneys, and brain. As a source of glucose, liver glycogen can restore postprandial
blood glucose levels when these become too low. Although galactose is also used for the synthesis
of a variety of oligosaccharides, glycoproteins, and glycolipids [129], it is not known to what extent
dietary galactose is used for this. At least in adults, the use of dietary galactose seems to be limited
and most galactose is produced endogenously from glucose. This is not, per se, the case in infants
and young children since they have much higher growth-related demands. Lactose intake has been
indicated to favor brain function in children; however, it is not clear if this can be directly linked to the
systemic galactose availability [133]. Lactose-derived galactose could be important in assuring the
metabolic flexibility required in infants/young children, because it acts in a non-insulinogenic way
(under fed conditions), and thereby lifts the ban (i.e., insulin) on fat metabolism [78]. Additionally,
for adults, the non-insulinogenic characteristic of lactose-derived galactose can be of interest in light of
metabolic health.
An often-mentioned benefit of lactose is its low glycemic index (GI). There is convincing evidence
from meta-analyses of controlled dietary trials that diets low in GI improve glycemic control in
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people with type 2 and type 1 diabetes. There is also convincing evidence from meta-analysis of
prospective cohort studies that low GI/GL diets reduce the risk of developing type 2 diabetes [77].
Consumption of lactose-containing dairy products is neutral or moderately beneficial to type 2 diabetes
risk [134]. Dairy consumption is sometimes linked to an increased type 1 diabetes risk, especially
in young children at risk (genetic predisposition for type 1 diabetes). Mechanistically, this is linked
to dairy proteins, specifically to A1 β-casein and its seven amino acid peptide β-casomorphin-7
(BCM-7) derivative, but not to lactose. The ecological relationship of milk A1 β-casein with type 1
diabetes across populations is strong. However, a causal role in its own right is unlikely [135]. There
is a similar relationship with vitamin D status, for which the putative mechanistic background in
(auto)immune disease is plausible [136,137]. Given the association of low vitamin D status with many
other immunologically-driven diseases, it seems possible that in the etiology of type 1 diabetes mellitus,
a low vitamin D phenotype interacts with A1 β-casein/BCM-7 or some other antigen(s), to which
the gut mucosa is exposed in early life. Interference with mucosal tolerance might be key. Recently,
an international, randomized clinical trial in 2159 infants at risk to present the disease, randomly
assigned to the consumption of a formula based on extensively hydrolyzed casein versus a formula
with intact milk protein, found no difference between groups in the incidence of type 1 diabetes after a
median follow-up of 11.5 years [138].
Lactose maldigestion is a result of too much lactose relative to lactase capacity. Lactase expression
reaches mature levels around term age [27–29]; this means that newborns and young children can digest
physiological amounts of lactose (i.e., as present in breastmilk) without any problems. Only when they
have no or low lactase expression due to congenital lactase deficiency, gastrointestinal infections, or to
preterm birth, can the digestion of lactose be compromised. Although LNP children and adults have a
considerably limited capacity to digest lactose, most of them should be able to deal with the fermentation
of 12 g of lactose in a single dose without having any relevant symptoms of lactose intolerance [5,70].
In about 35% of the world’s population, lactose can be digested, as lactase expression is continuous
(LP) due to SNPs that prevent the epigenetic silencing of lactase after weaning. No conclusive evidence
is available for a direct relationship between lactose intolerance and FGIDs [4,26,60,61]. Exclusion of
lactose containing milk and derived dairy products also implies a restriction in the intake of other
nutrients present in these products.
Widely-used glucose polymers in lactose-free infant formulae are digestible maltodextrins and
glucose syrups. Additionally, sucrose is sometimes used. It is unclear if these lactose replacements
are nutritionally equivalent to lactose, except regarding calories. When comparing lactose to sucrose,
various differences can be observed: (1) lactose contains glucose and galactose, while sucrose contains
glucose and fructose. Galactose and fructose have different metabolic behaviour inside the body;
(2) lactose contains a β1,4-glycosidic linkage, while sucrose contains an α1,2-glycosidic bond; (3) the GI
of lactose is 46, while the GI of sucrose is 65; (4) lactose has low sweetness and lacks rewarding effects
after consumption, while sucrose possesses high sweetness and elicits rewarding effects; (5) lactose
contains the versatile monosaccharide galactose which sucrose lacks; (6) lactose is less cariogenic
than sucrose; and (7) lactose exerts gut-microbiota-modulating effects that lead to increased uptake
of calcium, an effect not found for sucrose. Limited evidence suggests that maltodextrin is also not
equivalent to lactose. Maltodextrin, consisting of α-1,4 and α-1,6-linked D-glucose chains, may disrupt
host-microbial dynamics in the gut when it escapes digestion, and may be associated with the promotion
of E. coli colonization. A decision to replace lactose should take these differences into account.
5. Conclusions
Lactose is the preferred carbohydrate for infants and young children, for reasons that it (1) acts
as an excellent, slow release, energy source; (2) possibly contributes (in infants) to the synthesis of
complex glycosylated macromolecules by the provision of the building blocks glucose and galactose;
(3) elicits no reward effects after consumption; (4) has a low cariogenic effect (not discussed in this
paper); and (5) exerts gut microbiota-shaping effects, most likely promoting a more saccharolytic than
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proteolytic microbiota. Though some degree of lactose maldigestion will take place in all infants and
young children, this will seldomly lead to lactose intolerance symptoms. Additionally, in in LNP
adults and older children, dose-dependent fermentation of lactose takes place without symptoms
of intolerance almost always, while providing all the benefits of this fermentation. Considering all
above-mentioned benefits, the replacement of lactose by other carbohydrates has to be considered
with care and moderation.
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